Letendre Peter 4
4 · CORTEX PHARMACEUTICALS INC/DE/ · Filed Aug 20, 2012
Insider Transaction Report
Form 4
Letendre Peter
Director
Transactions
- Award
Common Stock
2012-08-10+684,031→ 684,031 total
Footnotes (1)
- [F1]Received in exchange for options to purchase 188,000 shares of Pier Pharmaceuticals, Inc. common stock and the right to receive $30,000 of cash consideration, all in connection with the merger among Cortex Pharmaceuticals, Inc., Pier Acquisition Corp. (a wholly-owned subsidiary of Cortex Pharmaceuticals, Inc.) and Pier Pharmaceuticals, Inc. (the "Merger"). On the effective date of the Merger, the closing price of the common stock of Cortex Pharmaceuticals, Inc. was $0.06 per share.